Research desk · ESPR · Nasdaq
ESPR Stock
SEC financials, peer compare, and chart. Scores open the matching desk. Research only — not advice.
Esperion Therapeutics, Inc. · Pharmaceutical Preparations
Esperion Therapeutics, Inc. financial statements, chart, and peer compare from SEC filings.
Esperion Therapeutics, Inc. (ESPR) discovers, develops, or markets pharmaceutical products.
- Market cap
- —
- P/E
- —
- Op. margin
- 16.21%
- Profit margin
- -39.45%
- FCF margin
- -17.42%
- ROE
- 49.65%
Related Health Care stocks: PTGX stock financials · INVA stock financials · ZLAB stock financials · ARQT stock financials · TWST stock financials
ESPR financial statements
Each Compare name is its own block of years. Filing lines are SEC reports; P/E and price sit on that name’s TTM column only.
ESPR stock peer compare
Each bar is that name’s percent vs its last TTM, on one zero line. Zero is unchanged. This ticker is the black bar.
Focus chart
Zero is unchanged vs last TTM. Every name is a percent for the metric you pick.
ESPR stock peer headlines
Yahoo Finance RSS for ESPR and the names in Compare.
| Ticker | Date | Headline |
|---|---|---|
| Loading headlines… | ||
ESPR stock price chart
Overlays follow the Compare table.
ESPR stock — research snapshot
Screen strengths and watchouts for ESPR stock from the latest Misprise snapshot.
Strengths
- ROE 49.7% — efficient equity returns.
- Operating margin 16.2% — solid operating leverage.
- Revenue CAGR 5Y 153.7% — durable top-line compound.
- Debt/equity 0.00 — leverage looks manageable.
- Current ratio 1.53 — liquidity cushion.
Watchouts
- ROA -33.1% — muted asset returns.
- Negative profit margin — earnings quality needs scrutiny.
- Negative FCF margin — cash generation is under pressure.
- EPS CAGR negative — earnings trajectory is soft.
- Rev CAGR 5Y 153.7%
- Rev CAGR 3Y 74.8%
- EPS CAGR 5Y -48.6%
- EPS CAGR 3Y -68.5%
- FCF CAGR 5Y -31.4%
- FCF CAGR 3Y -57.9%
ESPR stock FAQs
Short answers for ESPR stock — statements, sector, and how this page is meant to be used.
What is ESPR stock?
Esperion Therapeutics, Inc. (ESPR) discovers, develops, or markets pharmaceutical products. ESPR stock sits in Health Care (Pharmaceutical Preparations), listed on Nasdaq.
Where can I find Esperion Therapeutics, Inc. financial statements?
Esperion Therapeutics, Inc. financial statements — income statement, balance sheet, and cash flow — are on this ESPR stock page, parsed from SEC 10-K and 10-Q filings. Use Annual or Quarterly, then the statement tabs. Research only.
What happened to ESPR stock?
This page is a research snapshot of Esperion Therapeutics, Inc. (ESPR) from the latest SEC filings in the Misprise database as of TTM. It is not a news feed or a delisting notice. Open the financial statements, chart, and peer compare below, then read the filings. Research only — not financial advice.
Does this page show the ESPR stock price?
The live chart on this ESPR stock page is the same TradingView chart as the screener. Statement tables use SEC filings. Any price or multiple on the TTM column is a market snapshot from the last seed, not a real-time quote. Research only.
What sector is ESPR stock in?
Esperion Therapeutics, Inc. is classified in Pharmaceutical Preparations, inside the Health Care sector, and trades on Nasdaq. This page is a research snapshot, not a full company profile.
How do I read ESPR financial statements?
Start with this ticker’s block (TTM, then its fiscal years or quarters). Each Compare name is a separate block of its own periods — not mixed by year. A blank is a period we do not have, not a zero. Research only — not a buy or sell.
Where does the ESPR statement data come from?
Income, balance sheet, and cash-flow lines are parsed from SEC company filings (10-K / 10-Q and 20-F). TTM is the last four reported quarters added together, not a separate filing. P/E, forward P/E, price, and market cap are a market quote at last seed — trailing P/E from the quote when available, otherwise last price divided by TTM EPS. They are not 10-K line items and appear on the TTM column only. Research only — not financial advice.
Where can I find the ESPR income statement, balance sheet, and cash flow?
On this ESPR stock page, open Financial statements and use the Income, Balance sheet, and Cash flow tabs. Growth and valuation sit under More. Filing figures are from SEC reports; valuation multiples are the market snapshot described above.
What is the Misprise Score for ESPR stock?
ESPR stock currently scores 0/100 (Watch / incomplete (<60)). Esperion Therapeutics, Inc. scores weaker or incomplete on durable growth/quality inputs — leverage, coverage, and recent results deserve extra scrutiny. The score is a screen of quality, growth, and balance-sheet inputs — not a price target. Compare it in the Misprise screener; it is not a separate score page.
How is the ESPR comparison winner decided?
Lead and Tie follow the number printed on each factor row, not a blended category score. Growth, quality, score, current ratio, and coverage: the higher figure leads. Value multiples (P/E, PEG, P/B, P/S) and debt ratios: the lower figure leads. Tie appears only when those printed numbers match. The header winner is whoever takes more of those five rows. CAGR uses the 5-year horizon and drops to 3-year only when both names report it. Research only — not a buy or sell.
What is the Anomaly Score on this ESPR page?
Anomaly Score is how unusual a filing pattern is versus this company’s own history and its industry — not the same as Misprise Score. A high anomaly with a weak Misprise Score is often a noisy name. Open the anomaly detector to see the flag. Research only — not financial advice.
What does the green grant dot mean on ESPR stock?
A green circle next to the title means this ticker appears in the Misprise grants calendar with a recent federal award (USASpending / SAM). Tap the dot for date, agency, and amount when available. It is a research flag only — not a buy or sell signal.
Is ESPR stock a buy?
No recommendation either way. This ESPR stock page organizes statements, ratios, and peers so you can do your own work. It is educational only — not advice to buy or sell Esperion Therapeutics, Inc..